Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Database
Language
Publication year range
1.
Mol Cell ; 77(1): 82-94.e4, 2020 01 02.
Article in English | MEDLINE | ID: mdl-31630970

ABSTRACT

FUS is a nuclear RNA-binding protein, and its cytoplasmic aggregation is a pathogenic signature of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It remains unknown how the FUS-RNA interactions contribute to phase separation and whether its phase behavior is affected by ALS-linked mutations. Here we demonstrate that wild-type FUS binds single-stranded RNA stoichiometrically in a length-dependent manner and that multimers induce highly dynamic interactions with RNA, giving rise to small and fluid condensates. In contrast, mutations in arginine display a severely altered conformation, static binding to RNA, and formation of large condensates, signifying the role of arginine in driving proper RNA interaction. Glycine mutations undergo rapid loss of fluidity, emphasizing the role of glycine in promoting fluidity. Strikingly, the nuclear import receptor Karyopherin-ß2 reverses the mutant defects and recovers the wild-type FUS behavior. We reveal two distinct mechanisms underpinning potentially disparate pathogenic pathways of ALS-linked FUS mutants.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Frontotemporal Dementia/genetics , Mutation/genetics , RNA-Binding Protein FUS/genetics , RNA/genetics , Active Transport, Cell Nucleus/genetics , Glycine/genetics , Humans
2.
Mol Pharm ; 14(3): 614-625, 2017 03 06.
Article in English | MEDLINE | ID: mdl-28135100

ABSTRACT

There is current interest in harnessing the combined anticancer and immunological effect of nanoparticles (NPs) and RNA. Here, we evaluate the bioactivity of poly I:C (pIC) RNA, bound to anticancer zinc oxide NP (ZnO-NP) against melanoma. Direct RNA association to unfunctionalized ZnO-NP is shown by observing change in size, zeta potential, and absorption/fluorescence spectra upon complexation. RNA corona was visualized by transmission electron microscopy (TEM) for the first time. Binding constant (Kb = 1.6-2.8 g-1 L) was determined by modified Stern-Volmer, absorption, and biological surface activity index analysis. The pIC-ZnO-NP complex increased cell death for both human (A375) and mouse (B16F10) cell lines and suppressed tumor cell growth in BALB/C-B16F10 mouse melanoma model. Ex vivo tumor analysis indicated significant molecular activity such as changes in the level of phosphoproteins JNK, Akt, and inflammation markers IL-6 and IFN-γ. High throughput proteomics analysis revealed zinc oxide and poly I:C-specific and combinational patterns that suggested possible utility as an anticancer and immunotherapeutic strategy against melanoma.


Subject(s)
Antineoplastic Agents/pharmacology , Melanoma, Experimental/drug therapy , Nanoparticles/administration & dosage , Poly I-C/pharmacology , RNA/pharmacology , Zinc Oxide/pharmacology , Animals , Biomarkers, Tumor/metabolism , Cell Death/drug effects , Cell Line, Tumor , Humans , Interferon-gamma/metabolism , Interleukin-6/metabolism , MAP Kinase Kinase 4/metabolism , Melanoma, Experimental/metabolism , Mice , Mice, Inbred BALB C , Proto-Oncogene Proteins c-akt/metabolism
3.
PLoS One ; 15(12): e0243802, 2020.
Article in English | MEDLINE | ID: mdl-33326476

ABSTRACT

Zinc oxide (ZnO) NP is considered as a nanoscale chemotherapeutic. Thus, the drug delivery of this inorganic NP is of considerable importance. Ras mutations are common in cancer and the activation of this signaling pathway is a hallmark in carcinoma, melanoma and many other aggressive malignancies. Thus, here we examined the binding and delivery of Ras binding domain (RBD), a model cancer-relevant protein and effector of Ras by ZnO NP. Shifts in zeta potential in water, PBS, DMEM and DMEM supplemented with FBS supported NP interaction to RBD. Fluorescence quenching of the NP was concentration-dependent for RBD, Stern-Volmer analysis of this data was used to estimate binding strength which was significant for ZnO-RBD (Kd < 10-5). ZnO NP interaction to RBD was further confirmed by pull-down assay demonstrated by SDS-PAGE analysis. The ability of ZnO NP to inhibit 3-D tumor spheroid was demonstrated in HeLa cell spheroids-the ZnO NP breaking apart these structures revealing a significant (>50%) zone of killing as shown by light and fluorescence microscopy after intra-vital staining. ZnO 100 nm was superior to ZnO 14 nm in terms of anticancer activity. When bound to ZnO NP, the anticancer activity of RBD was enhanced. These data indicate the potential diagnostic application or therapeutic activity of RBD-NP complexes in vivo which demands further investigation.


Subject(s)
Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Nanoparticles , Zinc Oxide/metabolism , Zinc Oxide/pharmacology , ras Proteins/metabolism , Animals , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Cell Line, Tumor , Mice , Protein Binding , Zinc Oxide/chemistry , ras Proteins/chemistry
4.
J Biomed Nanotechnol ; 13(2): 221-31, 2017 Feb.
Article in English | MEDLINE | ID: mdl-29377653

ABSTRACT

Biomedical applications for metal and metal oxide nanoparticles are rapidly increasing. Here their functional impact on two well-characterized model enzymes, Luciferase (Luc) or ß-galactosidase (ß-Gal) was quantitatively compared. Nickel oxide nanoparticle (NiO-NP) activated ß-Gal (>400% control) and boron carbide nanoparticle (B4C-NP) inhibited Luc(<10% control), whereas zinc oxide (ZnO-NP) and cobalt oxide (Co3O4-NP) activated ß-Gal to a lesser extent and magnesium oxide (MgO) moderately inhibited both enzymes. Melanoma specific killing was in the order; ZnO > B4C ≥ Cu > MgO > Co3O4 > Fe2O3 > NiO, ZnO-NP inhibiting B16F10 and A375 cells as well as ERK enzyme (>90%) and several other cancer-associated kinases (AKT, CREB, p70S6K). ZnO-NP or nanobelt (NB) serve as photoluminescence (PL) cell labels and inhibit 3-D multi-cellular tumor spheroid (MCTS) growth and were tested in a mouse melanoma model. These results demonstrate nanoparticle and enzyme specific biochemical activity and suggest their utility as new tools to explore the important model metastatic foci 3-D environment and their chemotherapeutic potential.


Subject(s)
Antineoplastic Agents/pharmacology , Melanoma, Experimental/metabolism , Metal Nanoparticles/chemistry , Spheroids, Cellular/drug effects , Zinc Oxide/pharmacology , Animals , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Luciferases/analysis , Luciferases/drug effects , Luciferases/metabolism , Metals, Heavy/pharmacology , Mice , Zinc Oxide/chemistry , beta-Galactosidase/analysis , beta-Galactosidase/drug effects , beta-Galactosidase/metabolism
5.
Sci Rep ; 6: 33287, 2016 09 14.
Article in English | MEDLINE | ID: mdl-27624316

ABSTRACT

Two dimensional fluorescence difference spectroscopy (2D FDS) detects nanoparticle interactions following surface functionalization and biomolecule loading by generating a spectral signature of the fluorescent intensity per excitation and emission wavelengths. Comparing metal oxide nanoparticles revealed a unique spectral signature per material composition. 2D FDS showed to be sensitive to changes in surface properties between ZnO NPs synthesized by different methods. ZnO NP loaded with glycol chitosan, polyacrylic acid (PAA), or methoxy polyethylene glycol (mPEG) exhibited a distinct spectral signature shift. ZnO NP loaded with Torula Yeast RNA (TYRNA)(640 nm), polyinosinic: polycytidylic acid (pIC)(680 nm), or splice switching oligonucleotide (SSO)(650 nm) each revealed a shift in emission. Ras-Binding domain (RBD) at three concentrations (25, 37.5, 50 µg/mL) showed that fluorescent intensity was inversely related to the concentration of protein loaded. These data support 2D FDS as a novel technique in identifying nanoparticles and their surface interactions as a quality assurance tool.


Subject(s)
Drug Carriers/chemistry , Microscopy, Fluorescence , Nanoparticles/ultrastructure , Zinc Oxide/chemistry , Acrylic Resins/chemistry , Chitosan/chemistry , Nanoparticles/chemistry , Particle Size
6.
Anticancer Res ; 36(5): 2097-103, 2016 May.
Article in English | MEDLINE | ID: mdl-27127109

ABSTRACT

AIM: The effect of boron carbide (B4C) nanoparticles (NP) on protein-RNA complexes and metastatic phenotype of 3-D tumor spheroids was investigated. MATERIALS AND METHODS: Characterization was performed by transmission electron microscopy (TEM), zeta potential (ZP), 2-dimensional fluorescence difference spectroscopy (2-D FDS), gel electrophoresis, MTT, haemolysis and 3-D tumor spheroid assays. RESULTS: TEM showed NP were homogenous (≤50 nm) and spherical in shape. Zeta potential (ζ) of NP (-43.3) shifted upon protein:RNA interaction (+26.9). Protein:RNA complex interaction with NP was confirmed by 2-D FDS, demonstrating excitation/emission blue shift and lowered fluorescence intensity, and electrophoretic mobility shift assay (EMSA), where presence of B4C ablated visualization of the complex. B4C NP cytotoxicity was less than zinc oxide by MTT assay, protected haemolysis and effected 3-D tumor spheroid metastatic phenotype. CONCLUSION: Nanobio interface of B4C nanoparticles is unique and its anticancer potential may be mediated by altering protein and RNA interactions.


Subject(s)
Boron Compounds/chemistry , Nanoparticles/chemistry , Neoplasm Metastasis , Proteins/metabolism , RNA/metabolism , Spheroids, Cellular , Animals , Cell Line, Tumor , Humans , Microscopy, Electron, Transmission , Protein Binding , Spectrometry, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL